Drug intelligence / Profile preview

DD-1

Development stage: Preclinical
Lead developer: Allegro
Modality: Small Molecules

Overview

DD-1 is an early-stage therapeutic candidate developed by Allegro for the treatment of degenerative disc disease. It belongs to the company's proprietary 'Intricate' class of drugs, which are characterized as small molecules or complex chemical entities designed for musculoskeletal and rheumatological conditions. As of 2024, DD-1 is in the concept/R&D phase, with specific molecular targets and mechanisms of action remaining undisclosed by the developer. The 'DD' designation in its code name is a convention used by Allegro to signify its focus on degenerative disc pathology.

Targets

26S proteasome

Beyond the preview

Go deeper on DD-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DD-1.

Explore the full profile